WST (West Pharmaceutical Services) Research & Development: $74 Mil (TTM As of Mar. 2026)


WST West Pharmaceutical Services Inc WST
95 GF Score
Price $340.77
GF Value $361.52
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is West Pharmaceutical Services Research & Development?

West Pharmaceutical Services WST +1.30% 95 Research & Development is $74 Mil as of Mar. 2026. GuruFocus rates WST with a GF Score™ of 95/100 and a GF Value™ of $361.52 (Fairly Valued). The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. West Pharmaceutical Services's Research & Development for the three months ended in Mar. 2026 was $16 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $74 Mil.

West Pharmaceutical Services  (NYSE:WST) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

West Pharmaceutical Services Research & Development Related Terms

West Pharmaceutical Services Research & Development Historical Data

* Premium members only.

The historical data trend for West Pharmaceutical Services's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

West Pharmaceutical Services Research & Development Chart

West Pharmaceutical Services Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.80 58.50 68.40 69.10 74.30

West Pharmaceutical Services Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.30 19.10 17.10 21.80 15.80
WST
95GF Score
West Pharmaceutical Services Inc WST
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

West Pharmaceutical Services Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $74 Mil mean?
West Pharmaceutical Services (WST) has a Research & Development of $74 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on West Pharmaceutical Services and its competitors.
Is West Pharmaceutical Services' Research & Development too high?
West Pharmaceutical Services' current Research & Development is $74 Mil. Overall, West Pharmaceutical Services has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' Research & Development compare to RMD and MDLN?
West Pharmaceutical Services' Research & Development of $74 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on West Pharmaceutical Services and its competitors. West Pharmaceutical Services's current Research & Development is $74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (WST) is currently considered Fairly Valued. The stock's GF Value™ is $361.52, compared to a current price of $340.77 — trading 5.7% below its estimated fair value. The current Research & Development is $74 Mil. West Pharmaceutical Services' overall GF Score™ is 95/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For West Pharmaceutical Services (WST), the current Research & Development is $74 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is West Pharmaceutical Services (WST) Overvalued in 2026?

Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued. The current stock price of $340.77 is trading 5.7% below its estimated GF Value™ of $361.52. GuruFocus considers West Pharmaceutical Services to be Fairly Valued.

Key valuation signals for WST:

  • Research & Development: $74 Mil
  • GF Value™: $361.52 vs. price of $340.77 (5.7% below fair value)
  • GF Score™: 95/100 with 9 warning signs

No single metric tells the full story. See the WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

West Pharmaceutical Services Business Description

Address 530 Herman O. West Drive, Exton, PA, USA, 19341-1147
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
95GF Score

Get the complete analysis for WST

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$340.77
Price
$361.52
GF Value